Condition: Thrombotic Thrombocytopenic Purpura, Acquired · Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce. Therefore, the investigators aim at collecting evidence on a larger number of patients through a collaborative, international study.
This description comes directly from the study's public registry record.
Juri A Giannotta, M.D. · +390255035273 · juri.giannotta@policlinico.mi.it
Always discuss trial participation with your own doctor first.
| Angelo Bianchi Bonomi Hemophilia and Thrombosis Center | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07513948